Actively Recruiting
Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury
Led by Centre Hospitalier Universitaire, Amiens · Updated on 2025-05-28
105
Participants Needed
1
Research Sites
180 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Acute kidney injury (AKI) is a frequent disease in conventional hospital departments and in intensive care units. It's associated with a high risk to develop chronic kidney disease (CKD), even after a single small AKI episode. It's also associated with an important morbi-mortality, particularly cardiovascular (CV). Some studies have already showed a link between AKI and CV risk but pathologic mechanisms implicated are still unknown. In AKI and CKD, numerous substances, called uremic toxins (UT) are accumulating in blood. In CKD, those toxins, and particularly Indoxyl sulfate (IS), are known to have cardiac and vascular deleterious consequences. However, in AKI, whether acute accumulation of UT may trigger CV complications is unknown. The purpose of this study is that during AKI, a high UT concentration, in particular IS, would be associated with early vascular and cardiac dysfunctions that can be characterized by the persistence of an accelerated pulse wave velocity (PWV). The main objective is to evaluate the correlation between UT concentrations (especially IS) and arterial stiffness (PWV measurement) at three months of an AKI episode in conventional hospital departments and in the intensive care unit of nephrology.
CONDITIONS
Official Title
Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years old.
- Patients hospitalized in conventional hospital departments and in intensive care units of nephrology.
- Patients with moderate to severe AKI (KDIGO 2 or 3) without dialysis.
- AKI from functional or organic aetiology
You will not qualify if you...
- Patients with severe CKD (GFR<45ml/min/1.73 m2) or with kidney transplants.
- Patients with AKI from septic or obstructive aetiology.
- Patients with AKI from toxic aetiology whose toxic would be also responsible for cardiac toxicity.
- Patients with sepsis or blood inflammation.
- Patients with severe chronic cardiac dysfunction.
- Patients with arrhythmia or complete heart block.
- Patients with peripheral artery occlusive disease.
- Pregnancy.
- Patients on palliative care.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Amiens hospital
Amiens, France, 80000
Actively Recruiting
Research Team
P
Pauline Caillard, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here